Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Immunology pipeline completely backfills Humira gap by 2025.
Accelerated Humira Erosion: Biosimilar competition erodes Humira revenues significantly faster than projected, compressing margins.
AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend.
AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend.
Intellectual property and robust pipeline in immunology, oncology, and aesthetics.
Scale and distribution networks globally.
Aging population and increasing prevalence of autoimmune diseases drive secular volume growth. Innovation in targeted therapies commands premium pricing.
Hold.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
A severe margin contraction driven by pricing reform and aggressive biosimilar uptake stresses FCF. Debt load from Allergan acquisition amplifies equity risk, constraining dividend growth and leading to a structural multiple de-rating.
Intellectual property and robust pipeline in immunology, oncology, and aesthetics.
Scale and distribution networks globally.
Established brand equity in Botox and Humira.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $13.0B after capex $1.2B, with terminal value at 71.0% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If Skyrizi/Rinvoq beat expectations, hold/add. If Humira erodes >40% and margins crack, trim.
If Skyrizi/Rinvoq beat expectations, hold/add. If Humira erodes >40% and margins crack, trim.
If Skyrizi/Rinvoq beat expectations, hold/add. If Humira erodes >40% and margins crack, trim.
If Skyrizi/Rinvoq beat expectations, hold/add. If Humira erodes >40% and margins crack, trim.
Heavy R&D and M&A requirements create high barriers to entry. Capital flows to mega-cap incumbents with scale to navigate complex trials.
Aging population and increasing prevalence of autoimmune diseases drive secular volume growth. Innovation in targeted therapies commands premium pricing.
Patent cliffs induce brutal generic competition. Fiscal deficits pressure government healthcare budgets, capping price increases.
Heavy R&D and M&A requirements create high barriers to entry. Capital flows to mega-cap incumbents with scale to navigate complex trials.
Core income holding. Size at 3-5% of equity portfolio.
Trim above $240 or if the dividend becomes mathematically uncovered by free cash flow.
Hold. The current valuation perfectly balances the robust immunology transition against the ongoing Humira patent cliff. Collect the dividend while monitoring pipeline execution.
At $202.71, ABBV is fairly valued. The 19.36% market-implied growth rate introduces multiple contraction risk, but the 4%+ dividend yield and $13B FCF floor provide a sturdy anchor.
Hold. The current valuation perfectly balances the robust immunology transition against the ongoing Humira patent cliff. Collect the dividend while monitoring pipeline execution.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Biosimilars decimate Humira cash flows. Pipeline execution falters, triggering a multiple contraction to 12x as the dividend appears stressed.
Biosimilar competition erodes Humira revenues significantly faster than projected, compressing margins.
Key immunology assets fail to reach peak sales targets or face unexpected safety concerns.
Aggressive legislative action structurally reduces pricing power across the pharmaceutical portfolio.
The five developments that would weaken our investment case.
Accelerated biosimilar erosion outpacing new therapy growth would compress the top line, shrinking operating cash flows necessary to support debt service and ongoing pipeline acquisitions.
Current:8.6% for the period ended 2025-12-31
Alert ifturns negative or falls below 0.0% over any fiscal year
Underperformance in flagship immunology drivers would fail to compensate for legacy revenue losses, reducing corporate operating leverage and restricting free cash flow generation.
Current:32.8% for the period ended 2025-12-31
Alert ifcontracts below 25.0% over any four-quarter period
Unfavorable product mix shifts toward lower-margin therapies and severe pricing concessions would reduce gross profitability, leaving insufficient margin buffer to fund commercialization and clinical development programs.
Current:70.2% for the period ended 2025-12-31
Alert iffalls below 68.0% over any trailing twelve-month period
Diminished capital returns compounded by heavy acquisition debt burdens would impair corporate balance sheet resilience and limit the capacity to pursue future strategic business development.
Current:11.7% as of the report's 2026-05-08 analysis date
Alert ifdrops below 8.0% across any fiscal year
A sharp decline in operating cash generation relative to accounting profits would jeopardize dividend coverage and reduce internal liquidity required for debt paydown and pipeline expansion.
Current:4.503 as of the report's 2026-05-08 analysis date
Alert iffalls below 2.000 over any four-quarter period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
Immunology pipeline completely backfills Humira gap by 2025. Aesthetics rebounds with macro recovery. Terminal multiple expands to 17x on return to growth.
Humira erosion proceeds as guided. Skyrizi and Rinvoq deliver steady growth. The firm maintains $13B+ FCF, supporting the dividend at a 15x multiple.
Warning level: turns negative or falls below 0.0% over any fiscal year. Accelerated biosimilar erosion outpacing new therapy growth would compress the top line, shrinking operating cash flows necessary to support debt service and ongoing pipeline acquisitions.
Warning level: contracts below 25.0% over any four-quarter period. Underperformance in flagship immunology drivers would fail to compensate for legacy revenue losses, reducing corporate operating leverage and restricting free cash flow generation.
Warning level: falls below 68.0% over any trailing twelve-month period. Unfavorable product mix shifts toward lower-margin therapies and severe pricing concessions would reduce gross profitability, leaving insufficient margin buffer to fund commercialization and clinical development programs.
Warning level: drops below 8.0% across any fiscal year. Diminished capital returns compounded by heavy acquisition debt burdens would impair corporate balance sheet resilience and limit the capacity to pursue future strategic business development.
Warning level: falls below 2.000 over any four-quarter period. A sharp decline in operating cash generation relative to accounting profits would jeopardize dividend coverage and reduce internal liquidity required for debt paydown and pipeline expansion.
| $54.32B |
| $56.33B |
| $61.16B |
| +1.8% |
| Gross profit | $40.64B | $33.90B | $39.43B | $42.96B | +1.9% |
| Operating income | $15.71B | $8.47B | $6.52B | $9.49B | -15.5% |
| Net income | $11.84B | $4.86B | $4.28B | $4.23B | -29.1% |
| EPS (diluted) | $6.63 | $2.72 | $2.39 | $2.36 | -29.1% |
| EBITDA | $24.17B | $17.17B | $14.91B | $17.63B | -10.0% |
| R&D | $6.51B | $7.68B | $12.79B | $9.10B | +11.8% |
| SG&A | $15.26B | $12.87B | $14.75B | $14.01B | -2.8% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 61,160,000,000 |
|---|---|
| Cost of revenue | 18,204,000,000 |
| Gross profit | 42,956,000,000 |
| Operating expenses | 22,865,000,000 |
| Operating income | 20,091,000,000 |
| Non-operating items and tax | -15,865,000,000 |
| Net income | 4,226,000,000 |
| Total assets | 133,960,000,000 |
|---|---|
| Cash | 5,229,000,000 |
| Current assets | 29,062,000,000 |
| Total liabilities | 137,188,000,000 |
| Current liabilities | 43,289,000,000 |
| Shareholder deficit | 3,270,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | 22.8B | 22B | 787M | 8.5B | 692M | 934M | 9.3B | -8.4B | — | — | — | — | 9.7B | 76.7B | — | — | — | — |
| 2022-12-31 | 58.1B | 24.2B | 11.8B | 24.9B | 24.2B | 695M | 8.5B | 671M | 1.5B | 10B | -12.4B | — | — | — | — | 9.2B | 63.3B | 32.4% | — | 6.5% | — |
| 2023-12-31 | 54.3B | 17.2B | 4.9B | 22.8B | 22.1B | 777M | 8.7B | 747M | 2B | 10.5B | -4.1B | — | — | — | — | 12.8B | 59.4B | 24.9% | — | 6.1% | — |
| 2024-12-31 | 56.3B | 14.9B | 4.3B | 18.8B | 17.8B | 974M | 8.4B | 911M | 1.7B | 11B | 7.4B | — | — | — | — | 5.5B | 67.1B | 21.1% | — | 7.1% | — |
| 2025-12-31 | 61.2B | 17.6B | 4.2B | 19B | 17.8B | 1.2B | 8.1B | 955M | 980M | 11.7B | -304M | — | — | — | — | 5.2B | 67.5B | 32.8% | — | 6.1% | — |
ABBV trades at 12.5x forward earnings against a peer median of 14.0x; EV/EBITDA of 14.1x against a peer median of 13.2x; 6 peers.
| Level | Action |
|---|---|
| Thesis break | Trim above $240 or if the dividend becomes mathematically uncovered by free cash flow. |
| Johnson & Johnson |
| 17.5x |
| 5.6x |
| 16.6x |
| 26.4% |
| 27.4% |
| MRK | Merck & Co. Inc. | 11.8x | 4.2x | 11.0x | 18.9% | 38.6% |
| AMGN | Amgen Inc. | 14.0x | 4.8x | 13.2x | 101.3% | 33.8% |
| GILD | Gilead Sciences Inc. | 13.9x | 5.7x | 12.5x | 40.7% | 37.4% |
